EP.12A.32 Discontinuation of EGFR-TKI in NSCLC During COVID-19 Infection: Assessing Unvaccination, Low BMI, and Comorbidities

MLA

Huang, P., et al. “EP.12A.32 Discontinuation of EGFR-TKI in NSCLC During COVID-19 Infection: Assessing Unvaccination, Low BMI, and Comorbidities.” Journal of Thoracic Oncology, vol. 19, no. 10, Number 10 Supplement 1, Oct. 2024, pp. S633–34. EBSCOhost, https://doi.org/10.1016/j.jtho.2024.09.1191.

APA

Huang, P., Liao, L.-M., Zhao, J.-L., Luo, C., Yi, Y.-L., Chen, Y., & Huang, L. (2024). EP.12A.32 Discontinuation of EGFR-TKI in NSCLC During COVID-19 Infection: Assessing Unvaccination, Low BMI, and Comorbidities. Journal of Thoracic Oncology, 19(10, Number 10 Supplement 1), S633–S634. https://doi.org/10.1016/j.jtho.2024.09.1191

Chicago

Huang, P., L.-M. Liao, J.-L. Zhao, C. Luo, Y.-L. Yi, Y. Chen, and L. Huang. 2024. “EP.12A.32 Discontinuation of EGFR-TKI in NSCLC During COVID-19 Infection: Assessing Unvaccination, Low BMI, and Comorbidities.” Journal of Thoracic Oncology 19 (10, Number 10 Supplement 1): S633–34. doi:10.1016/j.jtho.2024.09.1191.